Every 8-K that Quantum Cyber N.V. (QUCY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow QUCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QUCY filings page.
Quantum Cyber N.V. furnished an investor presentation outlining its shift into an autonomous defense platform spanning air, ground and maritime domains, all built on a shared QC‑Core AI autonomy stack. The deck describes combat-experienced engineering teams and battlefield-validated designs from cooperation with Ukrainian forces, plus LOIs for SWARM‑X and FALCON 55 systems with General Cherry and SOCOM.
The materials emphasize eight filed patent positions and a signed exclusive worldwide license to Project LightShift’s quantum photonic array technology, feeding a quantum-enhanced autonomy roadmap. They also highlight a ~50,000 sq ft industrial facility at 38 Union Avenue, Bridgeport, Connecticut, acquired for $2, envisioned as an NDAA‑compliant US manufacturing base targeting 100,000 drones per year upon full buildout. Capital slides note about $15M raised via warrant exercises with all debt retired, termination of an at‑the‑market facility on June 12, 2026, 27 basic shares outstanding as of July 2026, and approximately $6M of CEO capital invested through convertible preferred shares subject to stockholder approval.
Quantum Cyber N.V. reported that its subsidiary Quantum Drones Corporation has completed the acquisition of certain real property at 38 Union Avenue, Bridgeport, Connecticut for a purchase price of $2,300,000. The property underlies an approximately 50,000-square-foot industrial facility intended to serve as a U.S.-based manufacturing site.
The acquisition completes the real-estate component of the broader Bridgeport transaction linked to a separate Asset Purchase Agreement for installed manufacturing equipment. Quantum Cyber describes this as a key step in its transition from technology development and licensing to vertically integrated autonomous defense manufacturing. The company also disclosed a corporate address change to Suite 400, 200 Connecticut Ave, Norwalk, CT 06854 and furnished a press release as an exhibit.
Quantum Cyber N.V. reported leadership changes and a new executive employment agreement. Its subsidiary Quantum Drones Corporation entered into a 12‑month employment agreement with Peter O’Rourke, effective July 1, 2026, under which he will serve as President of Quantum Drones.
Mr. O’Rourke will receive a monthly base salary of $20,833.33, reduced for the remainder of 2026 to $16,666.67 per month to reflect $50,000 in director fees, and stock options to purchase up to 112,859 ordinary shares at $1.45 per share. If terminated without Cause, he is entitled to one month of continued base salary plus accrued obligations.
The company also appointed Louis Buffalino to its Board of Directors, effective July 1, 2026, to fill a vacancy. He will serve until the 2027 annual general meeting, sit on the Audit, Compensation, and Nominating and Corporate Governance Committees, and receive standard non‑employee director compensation. The Board determined he qualifies as an independent director under Nasdaq rules.
Quantum Cyber N.V. is advancing its move into U.S. manufacturing through definitive agreements for the $3.2 million acquisition of the Arcade Metal Stamping business and its Bridgeport, Connecticut facility via subsidiary Quantum Drones Corporation. The deal covers substantially all operating assets plus the real property at 38 Union Avenue.
Quantum Drones agreed to pay $900,000 plus inventory value for the operating assets and $2,300,000 for the property, with a $300,000 deposit and $250,000 escrow to cover specified risks. A separate amendment to an IP license replaces a reimbursable cost structure with a $1,000,000 one-time cash payment to BP United for technical assistance, reinforcing the company’s shift toward vertically integrated autonomous defense manufacturing.
Quantum Cyber N.V. reported that its Audit Committee dismissed Reliant CPA as independent registered public accounting firm on June 22, 2026, and appointed Haskell & White LLP as the new auditor for the year ending December 31, 2026.
Reliant’s audit reports for the years ended December 31, 2025 and 2024 included a going concern paragraph, stating that significant operating losses raised substantial doubt about the company’s ability to continue as a going concern. The company states there were no disagreements or reportable events with Reliant, and it has not previously consulted Haskell & White on accounting or auditing matters described in the filing.
Quantum Cyber N.V. entered into an Intellectual Property License Agreement with Project LightShift, granting Quantum Cyber an exclusive worldwide license to quantum photonic array antenna technology for unmanned aerial vehicles and drone platforms used in defense and national security applications.
As consideration, Quantum Cyber will pay $1,000,000 in cash in installments and issue restricted ordinary shares valued at $5,000,000 over eight quarterly installments, subject to a six‑month lock-up and a 2% weighted average daily trading volume condition. Project LightShift is expected to deliver a demonstrable prototype by December 31, 2026, and Quantum Cyber gains a 120‑day exclusive right of first negotiation after successful demonstration. The company also signed a Voting Agreement under which LightShift agrees to vote its shares in favor of proposals recommended by Quantum Cyber’s board.
Quantum Cyber N.V. terminated its at-the-market issuance sales agreement with Maxim Group LLC, effective June 7, 2026, under the agreement’s terms. This arrangement, originally dated October 1, 2025 and amended May 4, 2026, allowed the company to sell shares into the market over time.
Before ending the program, Quantum Cyber sold 3,280,927 Ordinary Shares for net cash proceeds of about $4,388,515. The company states it will not owe any termination penalties, so ending the agreement does not trigger extra costs.
Quantum Cyber N.V. entered into Amendment No. 1 to its Intellectual Property License Agreement with BP United Inc., changing how their collaboration is structured. Instead of an exclusive supply agreement, BP United will provide manufacturing and consulting services, while the Company keeps the previously agreed $5,000,000 cash payment to fund ramp-up of its own manufacturing for Licensed Products.
The Consideration Shares become issuable at execution of the amendment and vest in four equal installments on September 30, 2026, March 31, 2027, June 30, 2027, and September 30, 2027. The filing also furnishes, under Regulation FD, a June 2026 corporate slide deck outlining Quantum Cyber’s autonomous defense platform, large target markets, patent portfolio, capital-light public structure with 22 shares outstanding, no debt and no warrants, and plans for a vertically integrated, NDAA‑aligned US manufacturing complex and contract-ready platforms supported by letters of intent with General Cherry and SOCOM.
Quantum Cyber N.V. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq’s Listing Qualifications Department confirmed that for 10 consecutive business days, from May 13, 2026 to May 27, 2026, the closing bid price of the company’s ordinary shares was at or above $1.00 per share.
As a result, the company now meets Nasdaq Listing Rule 5550(a)(2), and Nasdaq has closed the matter that began with a prior notice on March 20, 2026 regarding failure to maintain the minimum bid price.
Quantum Cyber N.V. filed an extensive business update and reported that all remaining warrants were exercised, generating over $15 million in gross proceeds and leaving the company debt-free. Management plans to use the funds to expand research and development, build its commercialization team, and pursue strategic acquisitions for its autonomous defense and quantum-AI platforms.
The filing also details the company’s pivot from its prior diagnostics focus to an AI- and quantum-enabled autonomous systems business, including an IP license and commercial supply relationship with BP United Inc. Quantum Cyber highlights heavy reliance on defense and government customers, stringent export-control and AI/UAV regulations, and emerging quantum and counter‑UAS markets. Risk factors emphasize Nasdaq minimum bid-price non-compliance, substantial potential dilution from preferred shares convertible into hundreds of millions of ordinary shares, evolving AI and UAV regulation, cybersecurity threats, and the early, volatile state of quantum computing markets.
Quantum Cyber N.V. entered into a significant Intellectual Property License Agreement with BP United Inc., gaining an exclusive, perpetual, fully paid-up worldwide license to commercialize technology across multiple applications, including drones and cyber technology. As consideration, subject to conditions precedent, the company agreed to pay $5,000,000 in cash and issue 20,000,000 restricted shares of common stock with a six-month lock-up and a five percent average weighted volume restriction.
The company may terminate the license and a related supply agreement within ninety days if due diligence and other conditions are not satisfied, and it can terminate the license at any time on notice. Quantum Cyber also entered into an Advisory Agreement with Alexander Gurevich, issuing 5,000,000 restricted ordinary shares at $0.40 per share for a 12‑month advisory term, and appointed Peter O’Rourke as a new director.
Quantum Cyber N.V. amended its Equity Distribution Agreement with Maxim Group LLC to raise the capacity of its at-the-market share offering program from $10,000,000 to up to $100,000,000 of ordinary shares.
The company also entered into a Consulting Agreement with Chief Financial Officer William Caragol, effective April 22, 2026. He will provide chief financial officer-level financial and accounting services for a monthly retainer of $20,000, with potential stock or option grants under the 2025 Omnibus Stock Plan at the board’s discretion. The consulting term runs through August 31, 2026 and may continue month to month, and either party can terminate with 30 days’ written notice.
Quantum Cyber N.V. reported completion of a private share sale that resulted in a change of control and broad boardroom changes. The company issued First Closing Shares for gross proceeds of $3 million on February 17, 2026 and had previously received $3 million as pre-payment for Second Closing Shares issued on April 22, 2026. These Second Closing Shares represented in excess of 90% of issued and outstanding ordinary shares on a fully diluted basis, and David E. Lazar became holder of over 95% of voting rights and the controlling shareholder. An Extraordinary General Meeting on April 22, 2026 approved all proposals, appointed David Natan and Avraham Ben‑Tzvi as directors, and coincided with the resignation of four prior directors and the Co‑Chief Executive Officer. The company also amended its Articles of Association while confirming its ordinary shares continue trading on the Nasdaq Capital Market under the symbol QUCY.
Mainz Biomed N.V. entered into an asset purchase agreement on April 9, 2026 to sell the intellectual property for its next generation colorectal cancer screening product candidates to an Italian buyer for $1.25 million. Closing is expected by April 23, 2026, subject to standard conditions and certain third-party consents, shipments and patent-related deadlines.
The company plans to use net proceeds to settle outstanding liabilities and for general corporate purposes. Management reiterates that winding down ColoAlert and next generation colorectal programs allows focus on a pancreatic cancer detection candidate and exploration of post-quantum cybersecurity opportunities.
Mainz Biomed previously reported stockholders’ equity of $641,600, below the $2.5 million minimum in Nasdaq Listing Rule 5550(b)(1). After receiving a total equity investment of $6 million in preferred shares in February and March 2026 and reducing monthly expenditures, the company believes its stockholders’ equity now exceeds $2.5 million and that it is currently in compliance with the Nasdaq listing requirement.
Mainz Biomed N.V. reported that Nasdaq has notified the company its ordinary shares no longer meet the minimum $1.00 bid price requirement, after trading below that level for 30 consecutive business days from February 5 to March 19, 2026. The company has 180 calendar days, until September 16, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days. If it does not regain compliance by then, it may qualify for an additional 180‑day period if it meets other initial listing standards and formally indicates an intention to cure, potentially via a reverse stock split. The notice has no immediate effect on the current Nasdaq listing, but failure to cure the deficiency could ultimately lead to delisting, which the company would have the right to appeal.